NRIX Nurix Therapeutics

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in September:

  • Wells Fargo Healthcare Conference

    Fireside chat: Wednesday, September 7 at 3:45 – 4:15 p.m. ET
  • Baird 2022 Global Healthcare Conference

    Fireside chat: Tuesday, September 13 at 10:50 – 11:20 a.m. ET

The events will be webcast live and may be accessed via a link in the Investors section of the Nurix website under . An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit .

Contacts:

Investors

Elizabeth Wolffe, Ph.D.

Wheelhouse Life Science Advisors

Media

Brett Whelan

LifeSci Communications



EN
31/08/2022

Underlying

NRIXNurix Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nurix Therapeutics

 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highl...

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWI...

April 28, 2025 1 EN
 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025...

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour   BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase degraders demonstrate potential to address both enzymatic and scaffolding functions and promote tumor regression in brain and small cell lung cancer models...

April 25, 2025 1 EN
 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 -...

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis Nurix to receive a $5 million milestone payment from Gilead for FDA clearance of the IND, bringing the total amount...

April 17, 2025 1 EN
 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule...

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on April 8, 2025, the company granted inducement awards to sixteen new employees. The grants were made pursuant to Nurix’s...

April 11, 2025 1 EN
 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Pr...

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 ...

April 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch